Patients with acute leukaemia who relapse after allogeneic haematopoietic stem cell transplantation (allo-HSCT) face limited treatment options. 1 Commonly, chemotherapy, novel agents like epigenetic modifiers, donor lymphocyte infusions (DLI), second allogeneic HSCT (allo-HSCT2), or combinations thereof are employed therapeutically. 1, 2 In general, outcome of patients with acute leukaemia relapsing after allo-HSCT remains poor. 1 The approach to relapse after allo-HSCT frequently is an individual one. The lack of head-to-head comparisons and small group sizes in the single analyses are an obstacle to evidence-based recommendations. Clearly, outcomes of cell-based therapy (DLI or allo-HSCT2) after successful induction of CR by conventional chemotherapy are superior to conventional chemotherapy alone if relapse occurred after reduced-intensity conditioning (RIC)-based allo-HSCT. 3 Recently, hypomethylating drugs as standalone agents or combined with DLI were shown to induce responses in 30-33% of patients. 4, 5 In addition, HDAC inhibitors, tyrosine-kinase inhibitors and Abs/Ab-conjugate combinations are in clinical tests at present. The value of allo-HSCT2 remains controversial. It is the one option with a documented long-time survival-10 year overall survival (OS) after myeloablative conditioning-based second allogeneic stem cell transplantation (allo-HSCT2) performed between 1985 and 2000 is 10 ± 2%. 6 Yet, what are the risk factors for successful allo-HSCT2 for relapse of acute leukaemia? Can choice of pretreatment, conditioning, immunosuppression or donor influence outcome?
Patients in CR at allo-HSCT2, relapsing no earlier than 10 months after allo-HSCT and transplanted using TBI-based conditioning at allo-HSCT2 reached a 10-year OS of 36 ± 10%. 6 Two of these favourable risk factors, ability to induce CR after haematological relapse after allo-HSCT1 and duration of remission, are factors commonly found to be prognostic for successful cell-based treatment, perhaps reflecting favourable disease biology. Risk factors for allo-HSCT2 have been evaluated in the myeloablative setting at allo-HSCTC [7] [8] [9] and in multicenter studies analysing both myeloablative and RIC regimens at allo-HSCT1/2. [10] [11] [12] Risk factors beyond duration of remission and ability to reach a next CR before allo-HSCT2 are less clear. Conducting allo-HSCT2 from an alternative donor in order to allow for an immune effect that was not provided by cells from the initial donor has not been proven to be beneficial. 9, 10, 13 Yet, the recent large study by Ruutu et al. 13 found a reduction in tumour-related mortality when an alternative donor was asked to donate. This was antagonised by lower non-relapse mortality (NRM) when the second graft was collected from the initial donor. 13 Due to small patient numbers in respective subgroups, valid statistical proof supporting or declassing the concept of changing the donor for individuals who had been in remission for a long time, who had not experienced GvHD after allo-HSCT1 and who do reach CR before allo-HSCT2 is lacking. The European Society for Blood and Marrow Transplantation (EBMT) risk score 14 at allo-HSCT2 was found to be of prognostic impact in several studies, 13, 15 excluding our own. 10 There still is considerable debate on the impact of the conditioning regimen chosen. In lower toxicity regimens at allo-HSCT2, NRM is frequently found to be reduced. 13, 16 Relapse incidence is sometimes documented to be increased. 9 Comparability between regimens throughout the transplant community is low due to little uniformity and results as to whether one or the other approach or even specific regimen trumps the other are to be viewed with caution.
This issue of Bone Marrow Transplantation features the largest analysis to date that exclusively focusses on patients who had received RIC before transplant at both allo-HSCT1 and allo-HSCT2, performed by the Acute Leukaemia Working Party (ALWP) of the EBMT. 17 In addition, this analysis sheds further light into the feasibility of a RIC-allo-HSCT2 after a RIC-allo-HSCT1 from an unrelated donor. Before an own 10 and two different analyses, 7, 8 reports on patients receiving an allo-HSCT2 after allo-HSCT1 from an unrelated donor were merely anecdotal. The findings of the study by Vrhovac et al. repeat in part what has been shown earlier and even stronger reflects the biology of the disease: the leading risk factor for relapse incidence (RI) and OS but not NRM after allo-HSCT2 is the duration of the interval from allo-HSCT1 to relapse. This has been found in basically every other analysis researching into risk factors for outcomes after allo-HSCT2 and does not seem to be restricted to acute leukaemias. 13 Yet additionally, Vrhovac and colleagues offer insights that had not been always addressed as clear as in their present analysis. Using the presence of cGvHD after allo-HSCT2 as a time-dependent variable the authors show a survival advantage for patients experiencing cGvHD after allo-HSCT2. The hazard ratio (HR) calculated on the occurrence of an event influencing OS was 0.51 (95% confidence interval (CI) 0.29-0.89), equalling a two-fold reduction of the likelihood of death due to any cause. Although NRM was not impacted in a statistically significant manner, the influence seen on RI (HR 0.52, 95% CI 0.27-1.03) and leukaemiafree survival (LFS, HR 0.56, 95% CI 0.31-1.00) supports the conclusion that the occurrence of cGvHD after allo-HSCT2 for acute leukaemia reduces risk of death by leukaemia by a factor of two. Schmid et al.
3 described cGvHD after RIC allo-HSCT1 to be of prognostic significance in univariate but not multivariate analysis, aGvHD was of significance in multivariate analysis. In the analysis of the ALWP published now, conditioning at allo-HSCT2 had a profound impact on OS at 2 years (17.4 (10.5-24.3)% for RIC vs 33.7 (20.4-47.1)% for nonmyeloablative (NMA)) in univariate analysis due to a significant reduction in NRM, with significance lost in multivariate analysis modeling factors with an influence on OS (HR 0.66, 95% CI 0.43-1.01) but still standing for the analysismodeling factors with an influence on NRM (HR 0.31, 95% CI 0.12-0.83). Higher age was of significant adverse risk for the occurrence of NRM in multivariate Cox regression. Karnofsky performance score with a threshold of 80% at allo-HSCT2 showed significant impact on OS in univariate analysis. As we 10 and others 9, 13 had suggested earlier, requesting a graft from a different donor at allo-HSCT2 as opposed to sticking to the same donor as for allo-HSCT1 did not show any advantage in this series as well. Finally, the authors constructed a model in which the time from allo-HSCT1 to relapse ( o225 days), failure to achieve CR at allo-HSCT2 and the use of a RIC (vs NMA) regimen were considered risk factors. Patients with all of these three factors absent showed a significantly superior OS at 2 years after allo-HSCT2 (60.6%, n = 13 patients) as compared with patients with one risk factor present (46.1%, n = 38 patients) and compared with patients with two or three risk factors present (12.3%, n = 141 patients). Of special interest, patients with acute lymphoblastic leukaemia who relapsed after allo-HSCT fared significantly worse than patients with AML and seem to constitute a group with a high research need.
Taken together, although RIC is associated with an increased risk of relapse, the combination of RIC at allo-HSCT1 and allo-HSCT2 results in a significant proportion of patients surviving. The work presented by Vrhovac and colleagues adds to the picture of options after relapse after allo-HSCT1 for acute leukaemia but many questions remain unanswered. Future attempts will, amongst others, have to focus on means of reducing leukaemia burden prior allo-HSCT2 and on means of using the allo-immune effect in a more effective way.
